Saigí Maria, Oliva Marc, Aliste Luisa, Calvo Mariona, Hormigo Gloria, Serra Òlbia, Boladeras Anna, Farran Leandre, Robles Javier, Creus Gloria, Paúles Ma José, Gornals Joan B, de Lama Eugenia, Borràs Josep Ma, Sala Núria, Galán Maica
Department of Medical Oncology, Institut Català Oncologia (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Gastroesophageal Tumours Functional Unit (UTEG), Institut Català d'Oncologia- Hospital Universitari de Bellvitge- IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
PLoS One. 2017 Sep 20;12(9):e0184737. doi: 10.1371/journal.pone.0184737. eCollection 2017.
Locally advanced esophageal carcinoma (LAEC) represents less than 30% of all diagnosed esophageal carcinoma worldwide. The standard of care for resectable tumours consists of preoperative chemoradiotherapy (CRT) followed by surgery. Despite the curative intent, the prognosis is still poor mainly due to relapse. A multidisciplinary approach is required in order to optimize the therapeutic strategy and follow-up. Differences in outcomes between the two main histological subtypes, adenocarcinoma (ADC) and squamous cell carcinoma (SCC), have been reported. Nevertheless, the heterogeneity in trials design and data available have hampered the achievement of clear conclusions. The purpose of this study is to report the outcomes from a cohort of patients with LAEC treated with a multidisciplinary approach and to remark the differences observed between the two main histologic subtypes and their clinical implications.
We retrospectively reviewed 100 patients diagnosed with LAEC that were treated with preoperative CRT at our institution and integrated centres. Histopathological characteristics and toxicities during treatment were recorded. Patterns of recurrence at the first relapse were analysed. Survival curves were plotted using the Kaplan Meier method and multivariate Cox proportional hazards models were used.
Among the patients who received preoperative CRT, 83% underwent surgery. The median overall survival (mOS) was 31.7 months, 26.9 months for ADC and 45.5 for SCC (p-value = 0.33). In the multivariate Cox regression analysis, ypN+ was the only factor that negatively influenced in OS (OR = 4.1, p-value = 0.022). Patterns of recurrence differed according to histologic subtype. Distant relapse was more frequent in ADC (62%), whereas locoregional relapse was higher in SCC (50%) (p-value = 0.027). Second line therapeutic strategies could be offered to 50% of those patients who relapsed.
Differences in outcomes and recurrence pattern could be observed between the two main histologic subtypes of LAEC. A better molecular characterization, adapted therapeutic regimens and follow up strategies should be adopted in order to improve survival of these patients.
局部晚期食管癌(LAEC)在全球所有确诊的食管癌中占比不到30%。可切除肿瘤的标准治疗方案包括术前放化疗(CRT),然后进行手术。尽管有治愈的意图,但预后仍然很差,主要原因是复发。需要采用多学科方法来优化治疗策略和随访。已有报道称两种主要组织学亚型,即腺癌(ADC)和鳞状细胞癌(SCC)的治疗结果存在差异。然而,试验设计和可用数据的异质性阻碍了得出明确的结论。本研究的目的是报告一组采用多学科方法治疗的LAEC患者的治疗结果,并指出两种主要组织学亚型之间观察到的差异及其临床意义。
我们回顾性分析了在我们机构及联合中心接受术前CRT治疗的100例LAEC患者。记录治疗期间的组织病理学特征和毒性反应。分析首次复发时的复发模式。采用Kaplan-Meier方法绘制生存曲线,并使用多变量Cox比例风险模型。
在接受术前CRT的患者中,83%接受了手术。中位总生存期(mOS)为31.7个月,ADC患者为26.9个月,SCC患者为45.5个月(p值 = 0.33)。在多变量Cox回归分析中,ypN+是唯一对总生存期有负面影响的因素(OR = 4.1,p值 = 0.022)。复发模式因组织学亚型而异。远处复发在ADC中更常见(62%),而局部区域复发在SCC中更高(50%)(p值 = 0.027)。50%复发患者可接受二线治疗策略。
LAEC的两种主要组织学亚型在治疗结果和复发模式上存在差异。应采用更好的分子特征分析、合适的治疗方案和随访策略,以提高这些患者的生存率。